Allegro DVT Fosters Adoption of MPEG-5 LCEVC Video Codec, Releases a Full Range of LCEVC Products
31.8.2023 16:00:00 EEST | Business Wire | Press release
Allegro DVT, a leading provider of Video codec compliance streams and silicon video IP solutions has launched a complete range of MPEG-5 LCEVC products comprising LCEVC compliance streams and LCEVC hardware decoder and encoder video IPs (D301 and E301).
Allegro DVT’s LCEVC Compliance Streams are crucial to confirm that decoder implementations adhere to the LCEVC standard. They are used by all companies developing SoCs or devices with LCEVC decoding capabilities.
Furthermore, Allegro DVT is also releasing its E301 LCEVC Encoding HW IP which complements its D301 LCEVC Decoding HW IP that was previously announced at NAB in April 2023. This full range of LCEVC HW IPs is suitable for integration into SoCs/ASICs requiring HW based support for LCEVC encoding and decoding functions.
The E301 is the industry’s first LCEVC encoding IP solution and was developed in close collaboration with V-Nova, the inventor of the LCEVC technology. It is optimized for power and silicon area, allows system-on-chip (SoC) and ASIC designers to easily integrate LCEVC encoding into their products. It supports picture resolution up to 8K, pixel widths from 8 to 12-bits and chroma subsampling formats ranging from 4:2:0 up to 4:4:4. The IP also features fast and easy SoC integration and is delivered with full user configurable control software.
Guido Meardi, CEO of V-Nova commented “As LCEVC continues its progression in the industry, a holistic suite of hardware IP tools including decoding, encoding, and verification platforms had become essential. Allegro DVT's offerings are perfectly timed to meet this emerging trend, reinforcing the momentum behind LCEVC. Their products will not only fuel LCEVC's adoption but also cement its position as a transformative force that many are already integrating into their plans.”
Nouar Hamze, CEO of Allegro DVT added “With today’s announcement, Allegro DVT has truly become a one-stop-shop for SoC/ASIC designers who need to rapidly add LCEVC encoding/decoding function into their products. Our E301 LCEVC Encoding IP, developed and benchmarked in collaboration with V-Nova, produces the best encoding video quality that fully unlocks the potential of the LCEVC technology. Together with our D301 LCEVC Decoding IP and LCEVC compliance streams, we are enabling an easy and seamless path for SoCs/ASIC companies to integrate and verify the new LCEVC standard into their products, giving them a tremendous competitive advantage.”
MPEG-5 part 2 LCEVC (Low Complexity Enhancement Video Coding) is the latest standard by MPEG and ISO. Instead of replacing existing codecs, LCEVC enhances them, reducing both costs and energy consumption of the transcoding process by up to 70%. Remarkably, it also augments compression efficiency by up to 40%, with benefits that stack upon those of other methods to improve video compression, rather than being an alternative. It specifies an enhancement layer which, when combined with a base video encoded with a separate codec, produces an enhanced video stream. LCEVC also enables unique benefits in applications such as single-stream SDR-HDR backward-compatible delivery and low-latency video delivery.
To find out more about Allegro DVT’s LCEVC products, come and visit Allegro DVT booth 5.A25 at IBC Amsterdam 15-18 September 2023.
About Allegro DVT
Allegro DVT is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on H.264, HEVC, VP9, AV1, VVC and LCEVC standards.
About V-Nova
V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 700 international patents, along with a range of software products and solutions.
For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831702100/en/
Contact information
Allegro DVT press:
Stéphanie Nastasi – Communication Manager
marcom@allegrodvt.com
V-Nova press:
Jose D. Guariglia – PR Account Manager, Bubble UK and EMEA
jd@bubbleagency.com
Casey Love – PR Account Manager, Bubble USA
caseyl@bubbleagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom